Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) EBITDA: 2009-2024

Historic EBITDA for Ligand Pharmaceuticals (LGND) over the last 16 years, with Dec 2024 value amounting to -$22.6 million.

  • Ligand Pharmaceuticals' EBITDA rose 1647.73% to $54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.5 million, marking a year-over-year increase of 207.32%. This contributed to the annual value of -$22.6 million for FY2024, which is 289.30% down from last year.
  • As of FY2024, Ligand Pharmaceuticals' EBITDA stood at -$22.6 million, which was down 289.30% from $11.9 million recorded in FY2023.
  • Ligand Pharmaceuticals' 5-year EBITDA high stood at $103.9 million for FY2021, and its period low was -$22.6 million during FY2024.
  • Moreover, its 3-year median value for EBITDA was $3.0 million (2022), whereas its average is -$2.5 million.
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 293.22% in 2023, then slumped by 289.30% in 2024.
  • Over the past 5 years, Ligand Pharmaceuticals' EBITDA (Yearly) stood at $37.5 million in 2020, then skyrocketed by 176.94% to $103.9 million in 2021, then slumped by 97.08% to $3.0 million in 2022, then soared by 293.22% to $11.9 million in 2023, then tumbled by 289.30% to -$22.6 million in 2024.